Pan-Tumor Approvals Stress the Need for Harmonized Testing and Reporting Strategies
Frontline Therapy Selection in HCC Hinges on Bleeding Risk and Patient-Specific Factors
FDA Grants Fast Track Status to SIGX1094 for Diffuse Gastric Cancer
Key HCC Trial Data Establish the Role of Later-Line Cabozantinib and Raise Further Frontline Questions